

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

**DELAY IN DESPATCH OF CIRCULAR
FOR THE MAJOR TRANSACTION
IN RELATION TO THE DISPOSAL OF
THE ENTIRE INTEREST IN A WHOLLY-OWNED SUBSIDIARY**

Reference is made to the announcements of Tongfang Kontafarma Holdings Limited (the “**Company**”) dated 27 June 2018 and 18 July 2018 (the “**Announcements**”), in relation to, among other things, the Disposal of the entire interest in a wholly-owned subsidiary of the Company and the delay in despatch of the Circular in relation to the Disposal and other information required under the Listing Rules. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcements.

As disclosed in the Announcements, the Circular was required to be despatched to the Shareholders on or before 19 July 2018 pursuant to Rule 14.41(a) of the Listing Rules. As additional time is required for the Company to prepare and finalise, among other things, financial information of the Group for inclusion in the Circular, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules and an extension of time for the despatch of the Circular (the “**Waiver**”). The Company hereby announces that the Stock Exchange has granted the Waiver to the Company, which allows the despatch date of the Circular to be postponed to a date falling on or before 24 August 2018.

By Order of the Board
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 23 July 2018

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Huang Yu (Chairman), Mr. Jiang Chaowen (Chief Executive Officer) and Mr. Ng Qing Hai; and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.